Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation

Journal of the American College of Cardiology

Volumn 32, Issue 2, 1998, Pages 393-397

  Niebauer, Josef ^a   Pflaum, Claus Dieter ^b   Clark, Andrew L ^c   Strasburger, Christian J ^b   Hooper, James ^a   Poole Wilson, Philip A ^a   Coats, Andrew J S ^a   Anker, Stefan D ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MUNICH   (Germany)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HYDROCORTISONE; NORADRENALIN; PRASTERONE; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AEROBIC CAPACITY; AGED; ARTICLE; BODY MASS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADRENERGIC ALPHA-AGONISTS; AGE FACTORS; AGED; ANATOMY, CROSS-SECTIONAL; BODY COMPOSITION; BODY MASS INDEX; CYTOKINES; DEHYDROEPIANDROSTERONE; DRUG RESISTANCE; ENERGY METABOLISM; EPINEPHRINE; HEART FAILURE, CONGESTIVE; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; INSULIN-LIKE GROWTH FACTOR I; LEG; MIDDLE AGED; MUSCLE CONTRACTION; MUSCLE, SKELETAL; NEUROPEPTIDES; NOREPINEPHRINE; OXYGEN CONSUMPTION; STROKE VOLUME; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT;

EID: 0032146343     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00226-5     Document Type: Article

References (35)

1. Volterrani M., Clark A.L., Ludman P.F., Swan J.W., Adamopoulos S., Piepoli M., Coats A.J.S. Determinants of exercise capacity in chronic heart failure. Eur Heart J. 15:1994;801-809.
2. Clark A.L., Poole-Wilson P.A., Coats A.J.S. Exercise limitation in chronic heart failure The central role of the periphery . J Am Coll Cardiol. 28:1996;1092-1102.
3. Anker S.D., Clark A.L., Kemp M., Salsbury C., Teixeira M.M., Hellewell P.G., Coats A.J.S. Tumor necrosis factor and steroid metabolism in chronic heart failure possible relation to muscle wasting . J Am Coll Cardiol. 30:1997;997-1001.
4. Anker S.D., Chua T.P., Ponikowski P., et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance in cardiac cachexia. Circulation. 96:1997;526-534.
5. Levine B., Kalman J., Mayer L., Fillit H., Packer M. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241.
6. McMurray J., Abdullah I., Dargie H.J., Shapiro D. Increased concentrations of tumour necrosis factor in 'cachectic' patients with severe chronic heart failure. Br Heart J. 66:1991;356-358.
7. Anker S.D., Egerer K.R., Volk H.-D., Kox W.J., Poole-Wilson P.A., Coats A.J.S. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol. 79:1997;1426-1430.
8. Opasich C., Pasini E., Aquilani R., et al. Skeletal muscle function at low work level as a model for daily activities in patients with chronic heart failure. Eur Heart J. 18:1997;1626-1631.
9. Anand I.A., Ferrari R., Kalra G.S., Wahi P.L., Poole-Wilson P.A., Harris P.C. Edema of cardiac origin studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure . Circulation. 80:1989;299-305.
10. Buller N.P., Poole-Wilson P.A. Mechanism of the increased ventilatory response to exercise in patients with chronic heart failure. Br Heart J. 63:1990;281-283.
11. Clark A.L., Poole-Wilson P.A., Coats A.J.S. The relationship between ventilation and carbon dioxide production in patients with chronic heart failure. J Am Coll Cardiol. 20:1992;1326-1332.
12. Buller N.P., Jones D., Poole-Wilson P.A. Direct measurement of skeletal muscle fatigue in patients with chronic heart failure. Br Heart J. 65:1991;20-24.
13. Anker S.D., Swan J.W., Volterrani M., et al. The influence of muscle mass, strength, fatiguability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J. 18:1997;259-269.
14. Jones D.A., Round J.M., Edwards R.H.T., Grindrod S.R., Tofts P.S. Size and composition of the calf and quadriceps in Duchenne muscular dystrophy. J Neurol Sci. 60:1983;307-322.
15. Mancini D.M., Walter G., Reichnek N., et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation. 85:1992;1364-1373.
16. Anker S., Ponikowski P., Varney S., et al. Wasting as an independent risk factor for mortality in chronic heart failure. Lancet. 349:1997;1050-1053.
17. Swan J.W., Walton C., Godsland I.F., Clark A.L., Coats A.J.S. Insulin resistance in chronic heart failure. Eur Heart J. 15:1994;1528-1532.
18. Swan J.W., Anker S.D., Walton C., et al. Insulin resistance in chronic heart failure relation to severity and etiology of heart failure . J Am Coll Cardiol. 30:1997;527-532.
19. Poehlman E.T., Scheffers J., Gottlieb S.S., Fisher M.L., Vaitekevicius P. Increased metabolic rate in patients with congestive heart failure. Ann Intern Med. 121:1994;860-862.
20. Matthews L.S., Norstadt G., Palmirez R.D. Regulation of insulin-like growth factor-1 gene expression by growth hormone. Proc Natl Acad Sci USA. 83:1986;9343-9347.
21. Underwood L.E., Van Wyk J.J. Normal and aberrant growth. Wilson J.D., Foster D.W. Williams Textbook of Endocrinology. 1992;1079-1138 WB Saunders, Philadelphia.
22. Fazio S., Sabatini L., Capaldo B., et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 334:1996;809-814.
23. Frustaci A., Gentiloni N., Russo M.A. Growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 335:1996;672-673.
24. Loh E., Swain J.L. Growth hormone for heart failure - cause for cautious optimism. N Engl J Med. 334:1996;856-857.
25. Kaleko M., Rutter W.G., Miller A.D. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastics transformation. Mol Cell Biol. 10:1990;464-473.
26. Singleton J.R., Randolph A.E., Feldman E.L. Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. Cancer Res. 56:1996;4522-4529.
27. Rodriguéz-Tarduchy G., Collins M.K., Garcia I., Lopez-Rivas A. Insulin-like growth factor-I inhibits apoptosis in IL-3-dependent hemopoietic cells. J Immunol. 149:1992;535-540.
28. Resnicoff M., Abraham D., Yutanawiboonchai W., et al. The insulin-like growth factor receptor protects tumor cells from apoptosis in vivo. Cancer Res. 55:1995;2463-2469.
29. Resnicoff M., Burgaud J.L., Rotman H.L., Abraham D., Baserga R. Correlation between apoptosis, tumorigenesis, and levels of insulin-factor I receptors. Cancer Res. 55:1995;3739-3741.
30. Arteaga C.L., Osborne C.K. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res. 49:1989;6237-6241.
31. Kalebic T., Tsokos M., Helman L.J. In vivo treatment with antibody against the IGF-I receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34/cdc2. Cancer Res. 54:1994;5531-5534.
32. Prager D., Li H.L., Asa S., Melmed S. Dominant negative inhibition of tumorgenesis in vivo by human insulin-like growth factor-I receptor mutant. Proc Natl Acad Sci. 91:1994;2181-2185.
33. Narula J., Haider N., Virmani R., et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 335:1996;1182-1189.
34. Olivetti G., Abbi R., Quaini F., et al. Apoptosis in the failing human heart. N Engl J Med. 336:1997;1131-1141.
35. Wu Y., Tewari M., Cui S., Rubin R. Activation of the insulin-like growth factor-I receptor inhibits tumor necrosis factor-induced cell death. J Cell Physiol. 168:1996;499-509.